REGN Q3 2022 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.9B-15.0% YoY

Gross Profit

$2.5B86.0% margin

Operating Income

$1.2B41.7% margin

Net Income

$1.3B44.8% margin

EPS (Diluted)

$11.66

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$629M

Free Cash Flow

$486M

Stock-Based Comp.

$166M

Balance Sheet

Total Assets

$27.7B

Total Liabilities

$6.2B

Stockholders' Equity

$21.4B

Cash & Equivalents

$3.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.9B	$3.5B	-15.0%
Gross Profit	$2.5B	$2.9B	-13.7%
Operating Income	$1.2B	$1.8B	-33.8%
Net Income	$1.3B	$1.6B	-19.4%

Revenue Segments

Product

$1.8B61%

Collaboration Revenue

$1.1B36%

Product and Service, Other

$84M3%